The cases of hereditary angioedema are increasing. The hereditary nature of the disease is passing the defective gene to the upcoming generations. This is expected to drive the growth of the Hereditary Angioedema market. The non-profit organizations are supporting the research on the disease that may lead to further growth in the market. Recently on June 7 2022, BioCryst Pharmaceuticals Inc., a company that designs and develops small molecule medicines for such rare diseases, announced that Swissmedic which is the Swiss Surveillance authority for medicines and medical devices, had given permission for marketing of oral, once in a day ORLADEYO for preventing routine recurrent hereditary angioedema that targets patients 12 years or older in Switzerland. The major factor that inhibits growth of the market are misdiagnosis of the disease and high drug costs.
According to Coherent Market Insights, Global Aereditary Angioedema Market is estimated to be valued at US$ 2,431.89 million in 2022 and is expected to exhibit a CAGR of 9.1% during the forecast period (2022-2030)
Leading Companies in the Hereditary Angioedema Industry:
1. CSL Limited
CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and allied products in Australia, the United States, Germany, the United Kingdom, Switzerland, China, and internationally. The company operates through two segments, CSL Behring and CSL Seqirus. CSL Limited was founded in 1916 and is headquartered in Parkville, Australia.
2. Takeda Pharmaceutical Company Limited
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan, the United States, Europe, Canada, Latin America, Russia, rest of Asia, and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, oncology, and neuroscience. Takeda Pharmaceutical Company Limited was founded in 1781 and is headquartered in Tokyo, Japan.
3. BioCryst Pharmaceuticals, Inc.
BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; Mundipharma International Holdings Limited; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. It is a biotechnology company, discovers novel, oral, and small-molecule medicines.
4. Ionis Pharmaceuticals, Inc.
Ionis Pharmaceuticals, Inc. was founded in 1989 and is based in Carlsbad, California. It has a strategic collaboration with Biogen Inc.; and collaboration and license agreement with AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis AG, Roche, Janssen Biotech, Inc., and Flamingo Therapeutics, Inc. Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States.
5. Arrowhead Pharmaceuticals, Inc.
Arrowhead Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Pasadena, California. Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States.
6. KalVista Pharmaceuticals, Inc.
KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors for diseases with unmet needs. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors. The company is headquartered in Cambridge, Massachusetts.
7. Centogene N.V.
Centogene N.V., together with its subsidiaries, focuses on rare diseases that transforms real-world clinical and genetic, or other data into actionable information for patients, physicians, and pharmaceutical companies worldwide. It operates through three segments: Pharmaceutical, Diagnostics, and COVID-19 testing. Centogene N.V. was founded in 2006 and is headquartered in Rostock, Germany. It has collaboration and license agreements with Shire International GmbH, Pfizer Inc., Dr. Bauer Laboratoriums GmbH, Fraport AG, Takeda Pharmaceutical Company Limited, and Twist Bioscience Corporation.
8. Sanofi
On November 2022, Sanofi along and GSK’s next generation COVID-19 booster vaccine VIdPrevtyn Beta have been approved by the European Commission and will be readily available for fall-winter COVID-19 vaccination campaigns in Europe. Sanofi operates through three segments: Pharmaceuticals, Vaccines, and Consumer Healthcare in in the United States, Europe, and internationally. Sanofi was founded in 1973 and is headquartered in Paris, France.
*Definition- A rare disorder hereditary Angioedema is linked to immune system, caused due to the absence of C1-esterase inhibitor which causes the blood vessel dilation.
